DelMar Pharmaceuticals Invited to Present New Data on VAL-083 in the Treatment of Glioblastoma Multiforme at the Society for NeuroOncology Annual Meeting
VANCOUVER, British Columbia, MENLO PARK, Calif. and MIAMI, Nov. 6, 2014 /PRNewswire/ --- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced that the Company has been invited to present three separate abstracts at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology being held November 13 to 16 in Miami. The presentations will detail continued advancement and new understandings in the research and development of VAL-083, a potential new therapy for refractory glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.
"We are pleased to be invited to present these data at the Society for NeuroOncology Annual meeting," stated Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals, Inc. "These presentations will highlight our continued clinical progress and provide further evidence to differentiate VAL-083 from today's standard of care in the treatment of GBM."
The details of DelMar's presentations are as follows:
Friday November 14, 12pm EST – Scientific Meeting Poster Session
Title: In vivo efficacy of VAL-083 in the treatment of MGMT-positive glioblastoma multiforme
Link to DelMar in vivo abstract DD-10
Friday November 14, 7:30pm EST – Evening Scientific Session
Title: VAL-083 is a novel N7 alkylating agent that inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant lines
Link to DelMar in vitro abstract ET-18
Title: Phase I/II study of dianhydrogalactitol (VAL-083) in patients with recurrent malignant glioblastoma multiforme (GBM)
Link to DelMar clinical abstract AT-53
"A major hurdle in the treatment of GBM is the resistance to currently approved chemotherapies such as temozolomide," added Mr. Bacha. "We know that VAL-083 works through a different mechanism of action and does not show susceptibility to the same resistance mechanisms. The data we have been invited to present will show further evidence, in both in vivo animal studies, in vitro disease models and from our clinical studies, that indicate VAL-083 has the potential to provide a viable treatment option for patients suffering from GBM who fail or are unlikely to respond to currently available chemotherapy."
VAL-083 (dianhydrogalactitol) is a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute (NCI), VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas. As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide). DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme patients.
About Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Approximately 15,000 people are diagnosed with glioblastoma each year in the U.S., with similar incidence in Europe. Standard of care is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy with temozolomide. Approximately 60 percent of GBM patients treated with temozolomide experience tumor progression within one year. More than half of glioblastoma patients will fail the currently approved therapies.
About the Society for Neuro-Oncology (SNO) annual meeting
The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. It is the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults. The 19th Annual Scientific Meeting and Education Day will be held November 13-16, 2014, at the Loews Hotel South Beach in Miami.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
For more information, please visit www.delmarpharma.com or follow us on Twitter @delmarpharma or Facebook.com/delmarpharma. Contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, firstname.lastname@example.org
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
SOURCE DelMar Pharmaceuticals, Inc.
Released November 6, 2014